Botox Therapeutic and Cosmetic, Juvederm, and Vraylar remained the main growth drivers of Allergan, which reported better than expected third quarter results. The pharma company posted a 3% decline in revenues to $3.91 billion due to a loss of exclusivity on some brands. Non-GAAP revenue rose 5.9%. Net loss for the quarter was $37.9 million or $0.11 per diluted share narrower than $3.95 billion or $11.84 per diluted share for the same period last year. Adjusted EPS rose 2.4% to $4.25. Key highlights of the results can be found in the infographics herewith https://news.alphastreet.com/allergan-q3-2018-earnings-agn-stock-results/
Why then are the Aesthetic Injectable Reps paid the least in the industry? It’s apalling, reps are leaving and great talent won’t come here because they value their worth. Look at the amount of money these reps are bringing in. WHY doesn’t this company pay them what they are worth??? It’s a joke. I just passed on a position here. Wouldn’t you want to take care of your employees who have built relationships with top accounts in this field?
